Virax Biolabs Group Ltd (NASDAQ:VRAX) does about 1.80M shares in volume on a normal day but saw 2014955 shares change hands in the recent trading day. The company now has a market cap of 13.50M USD. Its current market price is $3.11, marking an increase of 27.98% compared to the previous close of $2.43. The 52 week high reached by this stock is $9.00 whilst the lowest price level in 52 weeks is $0.60.
Virax Biolabs Group Ltd (VRAX) has a 20-day trading average at $1.96 and the current price is -65.44% off the 52-week high compared with 418.33% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.00 and its 200-day simple moving average is $1.72. If we look at the stock’s price movements over the week, volatility stands at 23.56%, which decreases to 17.14% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 71.32 to suggest the stock is overbought.
The consensus objective for the share price is $20.00, suggesting that the stock has a potential upside of 84.45% over the period.
The current price level is 59.08%, 55.61%, and 80.75% away from its SMA20, SMA50, and SMA200 respectively, with the VRAX price moving below the 50-day SMA on current market day. Virax Biolabs Group Ltd (VRAX) stock is up 48.10% over the week and 78.74% over the past month. Its price is 38.22% year-to-date and 146.83% over the past year.
To reach the target analysts have set, the stock logically needs to grow 84.45 percent from here.
The company has a return on investment of -73.30% and return on equity of -87.87%. The beta has a value of 1.67. Price to book ratio is 0.93 and price to sales ratio is 168.72.
